Biopharmaceutical firm Peregrine Pharmaceuticals has closed an offering for $5.75 million from six institutional investors, including a director at the Tustin, CA-based firm. With the new investment, Peregrine said it now has $11.6 million in cash to fund its clinical trials, contract manufacturing operations, and R&D. The offering was led by Zimmer Lucas Partners of New York City.
By AuntMinnie.com staff writersNovember 19, 2001
Related Reading
Biopharmaceutical firm Peregrine hawks new agents, September 19, 2001
Copyright © 2001 AuntMinnie.com